Evidence map›Paper›PMID 28747249›Full record

SynthesisEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology2017

Surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal cancer trials with preoperative therapy: Literature-based meta-analysis.

K Kataoka, K Nakamura, J Mizusawa, K Kato, J Eba, H Katayama, T Shibata, H Fukuda

Abstract readMeta-AnalysisReview
PubMed Publisher
In one paragraph

Synthesis in European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

K KataokaJCOG Data Center/Operations Office, Tokyo, Japan. Electronic address: kozokataoka@hotmail.co.jp.
K NakamuraJCOG Data Center/Operations Office, Tokyo, Japan.
J MizusawaJCOG Data Center/Operations Office, Center for Research Administration and Support, National Cancer Center, Japan.
K KatoGastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
J EbaJCOG Data Center/Operations Office, Tokyo, Japan.
H KatayamaJCOG Data Center/Operations Office, Tokyo, Japan.
T ShibataJCOG Data Center/Operations Office, Center for Research Administration and Support, National Cancer Center, Japan.
H FukudaJCOG Data Center/Operations Office, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere have been no reports evaluating progression-free survival (PFS) as a surrogate endpoint in resectable esophageal cancer. This study was conducted to evaluate the trial level correlations between PFS and overall survival (OS) in resectable esophageal cancer with preoperative therapy and to explore the potential benefit of PFS as a surrogate endpoint for OS.

methodsA systematic literature search of randomized trials with preoperative chemotherapy or preoperative chemoradiotherapy for esophageal cancer reported from January 1990 to September 2014 was conducted using PubMed and the Cochrane Library. Weighted linear regression using sample size of each trial as a weight was used to estimate coefficient of determination (R

resultsOf 614 articles, 10 trials were selected for the primary analysis and 15 for the sensitivity analysis. The primary analysis did not show a correlation between treatment effects on PFS and OS (R

conclusionAlthough the number of randomized controlled trials evaluating preoperative therapy for esophageal cancer is limited at the moment, PFS is not suitable for primary endpoint as a surrogate endpoint for OS.

Indexed as

Clinical Trials as TopicEsophageal NeoplasmsBiomarkersBiomarkers, TumorCombined Modality TherapyDisease-Free SurvivalGlobal HealthHumansPreoperative CareSurvival RateBiomarkersBiomarkers, TumorEsophageal cancerLiterature-based metaanalysisSurrogacy

Identifiers

PMID28747249

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.